Determining Adjuvant Therapy Through Recurrence Prediction: New Investigations - ILCN.org (ILCN/WCLC)
Real-World and Clinical Trial Validation of a Deep Learning Radiomic Biomarker for PD-(L)1 Immune Checkpoint Inhibitor Response in Advanced Non–Small Cell Lung Cancer | JCO Clinical Cancer Informatics,Hyperpolarized [1-13C]-pyruvate MRS evaluates immune potential and predicts response to radiotherapy in cervical cancer | European Radiology Experimental | Full Text,Determining Adjuvant Therapy Through Recurrence Prediction: New Investigations - ILCN.org (ILCN/WCLC),KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial: Cell Reports Medicine